Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011;6(8):e21268.
doi: 10.1371/journal.pone.0021268. Epub 2011 Aug 8.

Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip

Affiliations

Integrated proteomic and transcriptomic investigation of the acetaminophen toxicity in liver microfluidic biochip

Jean Matthieu Prot et al. PLoS One. 2011.

Abstract

Microfluidic bioartificial organs allow the reproduction of in vivo-like properties such as cell culture in a 3D dynamical micro environment. In this work, we established a method and a protocol for performing a toxicogenomic analysis of HepG2/C3A cultivated in a microfluidic biochip. Transcriptomic and proteomic analyses have shown the induction of the NRF2 pathway and the related drug metabolism pathways when the HepG2/C3A cells were cultivated in the biochip. The induction of those pathways in the biochip enhanced the metabolism of the N-acetyl-p-aminophenol drug (acetaminophen-APAP) when compared to Petri cultures. Thus, we observed 50% growth inhibition of cell proliferation at 1 mM in the biochip, which appeared similar to human plasmatic toxic concentrations reported at 2 mM. The metabolic signature of APAP toxicity in the biochip showed similar biomarkers as those reported in vivo, such as the calcium homeostasis, lipid metabolism and reorganization of the cytoskeleton, at the transcriptome and proteome levels (which was not the case in Petri dishes). These results demonstrate a specific molecular signature for acetaminophen at transcriptomic and proteomic levels closed to situations found in vivo. Interestingly, a common component of the signature of the APAP molecule was identified in Petri and biochip cultures via the perturbations of the DNA replication and cell cycle. These findings provide an important insight into the use of microfluidic biochips as new tools in biomarker research in pharmaceutical drug studies and predictive toxicity investigations.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Morphology of the HepG2/C3a cells after 96 hours of culture.
(A) biochip without APAP; (B) biochip treated with 1 mM of APAP; (C) Petri dish without APAP; (D) Petri dish treated with 1 mM of APAP.
Figure 2
Figure 2. APAP effect on cell proliferation and cell cycle repartition.
(A) Comparison of the cell growth in biochip and Petri dishes in untreated and treated conditions with 1 mM of APAP after 96 h of cultures (n = 6, * P<5%); (B) DNA repartition in biochip and Petri dishes after 96 hours of culture. The DNA repartition show for both culture conditions a disruption of the cell cycle repartition compared to control (n = 6* P<5%).
Figure 3
Figure 3. Principal Component Analysis.
(A) Proteomic analysis; (B) Transcriptomic analysis; (circles denote Petri data, triangles denote biochips data, black symbols are control data, white symbols are APAP data).
Figure 4
Figure 4. Mean genes and proteins affected by the culture condition.
(A) Mean genes differentially expressed by the environment condition and involved in hepatic differentiated function; (B) Mean proteins differentially expressed by the environment condition and involved in hepatic differentiated function.
Figure 5
Figure 5. Experimental design description.
(A) Perfusion setup and peristaltic pump setup with 6 individual biochips and medium reservoirs; (B) Microfluidic biochip; (C) Microchannel design inside of the biochip; (D) Experimental procedure.

Similar articles

Cited by

References

    1. Ferrer-Dufol A, Menao-Guillen S. Toxicogenomics and clinical toxicology: An example of the connection between basic and applied sciences. Toxicol Lett. 2009;186:2–8. - PubMed
    1. Oberemm A, Ahr HJ, Bannasch P, Ellinger-Ziegelbauer H, Glückmann M, et al. Toxicogenomic analysis of N-nitrosomorpholine induced changes in rat liver: Comparison of genomic and proteomic responses and anchoring to histopathological parameters. Toxicol Appl Pharmacol. 2009;241:230–245. - PubMed
    1. Veenstra TD. Proteomic approaches in drug discovery. Drug Discovery Today: Technologies. 2006;3:433–440.
    1. Sigdel TK, Sarwal MM. The proteogenomic path towards biomarker discovery. Pediatr Transplant. 2008;12:737–747. - PMC - PubMed
    1. Lee WM. Drug-Induced Hepatotoxicity. N Engl J Med. 2003;349:474–485. - PubMed

Publication types

MeSH terms